EXHIBIT 11
TITAN PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENT OF COMPUTATION OF NET INCOME (LOSS) PER SHARE
THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30,
--------------------------- -------------------------
1996 1997 1996 1997
----------- ----------- ------------ ------------
(unaudited) (unaudited)
Net income (loss) $(2,685,447) $ 4,217,077 $ (6,100,363) $(8,941,489)
Deemed dividend upon conversion of preferred stock - - (5,431,871) -
----------- ----------- ------------ ------------
Net loss applicable to common stock (2,685,447) 4,217,077 (11,532,234) (8,941,489)
----------- ----------- ------------ ------------
----------- ----------- ------------ ------------
Weighted average shares of
common stock outstanding 10,757,940 13,046,102 9,791,050 12,971,902
Common stock equivalents - 111,280 - -
----------- ----------- ------------ ------------
Shares used in computing net loss per share 10,757,940 13,157,382 9,791,050 12,971,902
----------- ----------- ------------ ------------
----------- ----------- ------------ ------------
Net income (loss) per share $ (0.25) $ 0.32 $ (1.18) $ (0.69)
----------- ----------- ------------ ------------
----------- ----------- ------------ ------------